SlideShare a Scribd company logo
1 of 1
All Records x/555 (%)
Renewals 550 (99.1)
Adaptations 5 (0.9)
Records of renewals x/550 (%)
Of a single medication in one encounter 379 (68.5)
Of multiple medications in one encounter 171 (31.5)
Reasons for
Renewal
Emergency supply 459 (83.5)
Upcoming appointment 65 (11.8)
Prescriber unavailable 21 (3.8)
Records of adaptations x/5 (%)
Type of
adaptation
Dose 3 (60)
Dosage Form 2 (40)
Regimen 0
Route of administration 0
• Changes needed to allow for future study
1) Data fields being collected
• Incorporate into modules the following fields: Days’ supply
authorized by RPh, prescriber characteristics (unique ID,
credentials, postal code), patient does not have primary care
prescriber for adaptations
• Make available the following fields for multiple renewals
performed in one encounter: DIN, medication name, strength,
route of administration, quantities authorized and dispensed
by RPh
2) Number of RPh routinely documenting
• More RPh in greater variety of jurisdictions over longer time
frame
• Unclear if more renewals than adaptations documented
because:
i. renewals happen more frequently,
ii. differences in requirement for notifying prescribers
between renewals and adaptations, or
iii. differences in ease of documentation with e-modules
Results Discussion
Uptake of Authority to Renew and Adapt Prescriptions by Ontario
Community Pharmacists: A Preliminary Investigation
Rebecca Babaei-Rad1-3, Thomas Huang2-3, Elizabeth Bojarski2,3, Lisa McCarthy1-4
1Women’s College Hospital, 2University of Toronto, 3Ontario Pharmacy Research Collaboration (OPEN), 4Women’s College Research Institute
Table 1. Desirable data fields found to be currently available or unavailable within the renewals and adaptations
documentation e-modules
• Design: Feasibility evaluation
• Process:
• Research team brainstormed and compiled desired variables
• Desired variables presented to partners who advised which
ones are currently captured in e-modules
• Data sharing agreement developed, ethics approval obtained
• Data file covering all renewals and adaptations recorded in e-
modules since inception of the system (Feb 2014) to Mar 2015
supplied to OPEN
• OPEN team conducted descriptive analysis, determined
feasibility of retrospective cohort study and developed
recommendations for next steps
Table 2. Descriptions of renewals and adaptations
documented
Acknowledgements
• Thank-you to Nikki Roy and Linda Perfetto (PASI), Michael Nashat and
Sandra Hanna (OnPharm Inc.) for their partnership on this project and
to Abhijeet Minhas for his critical review of this poster.
• This research project was supported by a grant from the Government
of Ontario. The views expressed in this poster are those of the
presenters and do not necessarily reflect those of the funder.
Introduction
Methods
• In October 2012 Ontario pharmacists (RPh) gained authority to
independently renew and adapt prescriptions, however to date
there has been no evaluation of the uptake of these services
• RPh documentations serve as data sources but earlier work
examining hard-copy prescription records proved too resource
intensive for a wider-scale audit
• We partnered with:
• OnPharm Inc. (OP) - supports 230 independent pharmacies in
Ontario
• Pharmacy Access Solutions Inc. (PASI) - a pharmacy
documentation database vendor
• Together they had developed e-modules for renewals and
adaptations to be used by OP-member RPh
• Overall Aim: To explore whether data from e-modules is useful for
estimating uptake of renewal and adaptation authority
• Research Questions:
• What variables (data fields) are desired for a study describing
whether and to what extent RPh are renewing and adapting
prescriptions?
• How useful is the currently available data?
• Are the desired data fields currently being documented in
the existing system?
• Are a reasonable number of Ontario RPh adequately
entering data into the documentation system?
Category Currently Available Currently Unavailable
Patient unique ID, gender, birth year, postal code
Pharmacist (RPh) unique ID
Pharmacy unique ID, postal code mean daily prescription volume
Prescription (Rx)
unique ID (Rx number), date of Rx, DIN, AHFS classification,
medication name, strength, route of administration, number of
refills for last filled Rx, quantity authorized for last filled Rx
Renewal
reason for renewal, quantity authorized by RPh, quantity dispensed
by RPh, patient does not have primary care prescriber (Y/N), method
of notification of primary care prescriber (phone, fax, other)
days’ supply authorized by RPh
Adaptation
type of adaptation, quantity authorized by RPh, quantity dispensed
by RPh, notification to prescriber (Y/N), method of notification of
prescriber (phone, fax, other)
days’ supply authorized by RPh,
patient does not have primary
care prescriber (Y/N)
Prescriber unique ID, credentials, postal code
• A retrospective cohort study estimating the uptake of renewals and
adaptations through review of RPh clinical e-documentation is not
feasible at this time
• Analysis of data collected through e-modules feasible though
changes to modules desirable to increase usefulness of data
• Enhanced usage of the documentation modules by RPh in a
greater number of jurisdictions is required for evaluating
uptake of prescriptive authority
Conclusions
Fig 1. Percentage of adaptations and renewals
completed by each RPh in the two
pharmacies from which data were collected
ID, identifier; DIN, drug identification number; AHFS, American Hospital Formulary System
Pharmacy 1 Pharmacy 2
100%
0% 0% 0% 0% 0% 0% 0%
55%
15% 15%
7%
4% 1% 1% 1%
RPh 1 RPh 2 RPh 3 RPh 4 RPh 5 RPh 6 RPh 7 RPh 8
PercentageofAdaptations/Renewals
Adaptations Renewals

More Related Content

What's hot

Canada Market Access Briefing
Canada Market Access BriefingCanada Market Access Briefing
Canada Market Access Briefing
Michael Jacobson
 
Data mining approaches to signal detection
Data mining approaches to signal detectionData mining approaches to signal detection
Data mining approaches to signal detection
Bhaswat Chakraborty
 

What's hot (20)

IAOS 2018 - Is drug statistics part of official statistics?, A. Me
IAOS 2018 - Is drug statistics part of official statistics?, A. MeIAOS 2018 - Is drug statistics part of official statistics?, A. Me
IAOS 2018 - Is drug statistics part of official statistics?, A. Me
 
Funding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program PerspectiveFunding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program Perspective
 
Effective Patient Advocacy: Problem + Solution = Collaboration
Effective Patient Advocacy: Problem + Solution = CollaborationEffective Patient Advocacy: Problem + Solution = Collaboration
Effective Patient Advocacy: Problem + Solution = Collaboration
 
Ira Klein, Can Value-based Contracting Work for Pharma Companies?
Ira Klein, Can Value-based Contracting Work for Pharma Companies?Ira Klein, Can Value-based Contracting Work for Pharma Companies?
Ira Klein, Can Value-based Contracting Work for Pharma Companies?
 
Oncology Dynamics - IQVIA
Oncology Dynamics - IQVIAOncology Dynamics - IQVIA
Oncology Dynamics - IQVIA
 
STREAM THREE: Jeff Keefer, Inclusion in Clinical Trials
STREAM THREE: Jeff Keefer, Inclusion in Clinical Trials STREAM THREE: Jeff Keefer, Inclusion in Clinical Trials
STREAM THREE: Jeff Keefer, Inclusion in Clinical Trials
 
Canada Market Access Briefing
Canada Market Access BriefingCanada Market Access Briefing
Canada Market Access Briefing
 
Cathy parker the orphan drug framework
Cathy parker the orphan drug frameworkCathy parker the orphan drug framework
Cathy parker the orphan drug framework
 
Patient Group Development and Engagement
Patient Group Development and EngagementPatient Group Development and Engagement
Patient Group Development and Engagement
 
Latin America´s Role In Clinical Studies
Latin America´s Role In Clinical StudiesLatin America´s Role In Clinical Studies
Latin America´s Role In Clinical Studies
 
Glenn Monteith expert patients forum
Glenn Monteith  expert patients forumGlenn Monteith  expert patients forum
Glenn Monteith expert patients forum
 
Clinical Drug Information
Clinical Drug InformationClinical Drug Information
Clinical Drug Information
 
Vers une Stratégie québécoise en matière de maladies rares
Vers une Stratégie québécoise en matière de maladies raresVers une Stratégie québécoise en matière de maladies rares
Vers une Stratégie québécoise en matière de maladies rares
 
Data mining approaches to signal detection
Data mining approaches to signal detectionData mining approaches to signal detection
Data mining approaches to signal detection
 
A Brief History of the CDFI
A Brief History of the CDFIA Brief History of the CDFI
A Brief History of the CDFI
 
Private Insurance Plans - Do they have a future in Canada?
Private Insurance Plans - Do they have a future in Canada?Private Insurance Plans - Do they have a future in Canada?
Private Insurance Plans - Do they have a future in Canada?
 
Reconciliation and Literature Review and Signal Detection_Katalyst HLS
Reconciliation and Literature Review and Signal Detection_Katalyst HLSReconciliation and Literature Review and Signal Detection_Katalyst HLS
Reconciliation and Literature Review and Signal Detection_Katalyst HLS
 
RWD/RWE for Rare Disease Drugs Webinar
RWD/RWE for Rare Disease Drugs WebinarRWD/RWE for Rare Disease Drugs Webinar
RWD/RWE for Rare Disease Drugs Webinar
 
Medical Writing Canada
Medical Writing CanadaMedical Writing Canada
Medical Writing Canada
 
Hta barriers to ideal
Hta barriers to idealHta barriers to ideal
Hta barriers to ideal
 

Viewers also liked (9)

Lane ePrescribe
Lane ePrescribeLane ePrescribe
Lane ePrescribe
 
Rx15 pdmp wed_1115_1_kreiner_2ringwalt
Rx15 pdmp wed_1115_1_kreiner_2ringwaltRx15 pdmp wed_1115_1_kreiner_2ringwalt
Rx15 pdmp wed_1115_1_kreiner_2ringwalt
 
High Intensity Prescribers in the ED
High Intensity Prescribers in the EDHigh Intensity Prescribers in the ED
High Intensity Prescribers in the ED
 
ePrescribe Controlled Substances With Ease
ePrescribe Controlled Substances With EaseePrescribe Controlled Substances With Ease
ePrescribe Controlled Substances With Ease
 
Pharmacy – Requirements, Standards, Architecture & Implementation
Pharmacy – Requirements, Standards, Architecture & ImplementationPharmacy – Requirements, Standards, Architecture & Implementation
Pharmacy – Requirements, Standards, Architecture & Implementation
 
National drug policy of Nepal
National drug policy of NepalNational drug policy of Nepal
National drug policy of Nepal
 
Fackler Grand Rounds - 2016 CDC Opioid Guideline
Fackler Grand Rounds - 2016 CDC Opioid GuidelineFackler Grand Rounds - 2016 CDC Opioid Guideline
Fackler Grand Rounds - 2016 CDC Opioid Guideline
 
4.0 guidelines for prescribing glasses in children
4.0 guidelines for prescribing glasses in children4.0 guidelines for prescribing glasses in children
4.0 guidelines for prescribing glasses in children
 
Authority To Refill Existing Prescriptions Mo
Authority To Refill Existing Prescriptions MoAuthority To Refill Existing Prescriptions Mo
Authority To Refill Existing Prescriptions Mo
 

Similar to PASI Poster OPEN Template

Pdmp 4-20kreiner-small-140501094202-phpapp02
Pdmp 4-20kreiner-small-140501094202-phpapp02Pdmp 4-20kreiner-small-140501094202-phpapp02
Pdmp 4-20kreiner-small-140501094202-phpapp02
pmppowerpoint
 
How to design effective and efficient real world trials TB Evidence 2014 10.2...
How to design effective and efficient real world trials TB Evidence 2014 10.2...How to design effective and efficient real world trials TB Evidence 2014 10.2...
How to design effective and efficient real world trials TB Evidence 2014 10.2...
Todd Berner MD
 
RDF Quantification-Orientation material for 2014.pptx
RDF Quantification-Orientation material for 2014.pptxRDF Quantification-Orientation material for 2014.pptx
RDF Quantification-Orientation material for 2014.pptx
gizachewyohannesgtg
 
CoArtha Technolsolutions IT for Meaningful Use
CoArtha Technolsolutions IT for Meaningful UseCoArtha Technolsolutions IT for Meaningful Use
CoArtha Technolsolutions IT for Meaningful Use
MapRecruit.com
 
Fronzi (Ghc)
Fronzi (Ghc)Fronzi (Ghc)
Fronzi (Ghc)
TORC
 
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebranRevised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
OPUNITE
 
Meaningful use stage-1
Meaningful use stage-1Meaningful use stage-1
Meaningful use stage-1
preeti_ipc
 

Similar to PASI Poster OPEN Template (20)

Med Rec And Terminology To Mcp 2008
Med Rec And Terminology To Mcp 2008Med Rec And Terminology To Mcp 2008
Med Rec And Terminology To Mcp 2008
 
11456346.ppt
11456346.ppt11456346.ppt
11456346.ppt
 
Documentation and Reporting
Documentation and ReportingDocumentation and Reporting
Documentation and Reporting
 
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiroWeb only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
 
Kelly Clark
Kelly ClarkKelly Clark
Kelly Clark
 
Leonard Young CORRECT
Leonard Young CORRECTLeonard Young CORRECT
Leonard Young CORRECT
 
CPT.RWE for decision making.2016
CPT.RWE for decision making.2016CPT.RWE for decision making.2016
CPT.RWE for decision making.2016
 
Pdmp 4 kreiner small
Pdmp 4 kreiner smallPdmp 4 kreiner small
Pdmp 4 kreiner small
 
Pdmp 4-20kreiner-small-140501094202-phpapp02
Pdmp 4-20kreiner-small-140501094202-phpapp02Pdmp 4-20kreiner-small-140501094202-phpapp02
Pdmp 4-20kreiner-small-140501094202-phpapp02
 
How to Define Effective and Efficient Real World Trials
How to Define Effective and Efficient Real World TrialsHow to Define Effective and Efficient Real World Trials
How to Define Effective and Efficient Real World Trials
 
How to design effective and efficient real world trials TB Evidence 2014 10.2...
How to design effective and efficient real world trials TB Evidence 2014 10.2...How to design effective and efficient real world trials TB Evidence 2014 10.2...
How to design effective and efficient real world trials TB Evidence 2014 10.2...
 
How Medication Adherence and Specialty Drugs Impact Employer Healthcare Costs
How Medication Adherence and Specialty Drugs Impact Employer Healthcare CostsHow Medication Adherence and Specialty Drugs Impact Employer Healthcare Costs
How Medication Adherence and Specialty Drugs Impact Employer Healthcare Costs
 
RDF Quantification-Orientation material for 2014.pptx
RDF Quantification-Orientation material for 2014.pptxRDF Quantification-Orientation material for 2014.pptx
RDF Quantification-Orientation material for 2014.pptx
 
The Role of Real-World Evidence in Supporting a Product's Value Story
The Role of Real-World Evidence in Supporting a Product's Value StoryThe Role of Real-World Evidence in Supporting a Product's Value Story
The Role of Real-World Evidence in Supporting a Product's Value Story
 
Knowledge managementneedsinprescriptionmedicationprocess
Knowledge managementneedsinprescriptionmedicationprocessKnowledge managementneedsinprescriptionmedicationprocess
Knowledge managementneedsinprescriptionmedicationprocess
 
CoArtha Technolsolutions IT for Meaningful Use
CoArtha Technolsolutions IT for Meaningful UseCoArtha Technolsolutions IT for Meaningful Use
CoArtha Technolsolutions IT for Meaningful Use
 
17 action plan
17 action plan17 action plan
17 action plan
 
Fronzi (Ghc)
Fronzi (Ghc)Fronzi (Ghc)
Fronzi (Ghc)
 
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebranRevised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
 
Meaningful use stage-1
Meaningful use stage-1Meaningful use stage-1
Meaningful use stage-1
 

PASI Poster OPEN Template

  • 1. All Records x/555 (%) Renewals 550 (99.1) Adaptations 5 (0.9) Records of renewals x/550 (%) Of a single medication in one encounter 379 (68.5) Of multiple medications in one encounter 171 (31.5) Reasons for Renewal Emergency supply 459 (83.5) Upcoming appointment 65 (11.8) Prescriber unavailable 21 (3.8) Records of adaptations x/5 (%) Type of adaptation Dose 3 (60) Dosage Form 2 (40) Regimen 0 Route of administration 0 • Changes needed to allow for future study 1) Data fields being collected • Incorporate into modules the following fields: Days’ supply authorized by RPh, prescriber characteristics (unique ID, credentials, postal code), patient does not have primary care prescriber for adaptations • Make available the following fields for multiple renewals performed in one encounter: DIN, medication name, strength, route of administration, quantities authorized and dispensed by RPh 2) Number of RPh routinely documenting • More RPh in greater variety of jurisdictions over longer time frame • Unclear if more renewals than adaptations documented because: i. renewals happen more frequently, ii. differences in requirement for notifying prescribers between renewals and adaptations, or iii. differences in ease of documentation with e-modules Results Discussion Uptake of Authority to Renew and Adapt Prescriptions by Ontario Community Pharmacists: A Preliminary Investigation Rebecca Babaei-Rad1-3, Thomas Huang2-3, Elizabeth Bojarski2,3, Lisa McCarthy1-4 1Women’s College Hospital, 2University of Toronto, 3Ontario Pharmacy Research Collaboration (OPEN), 4Women’s College Research Institute Table 1. Desirable data fields found to be currently available or unavailable within the renewals and adaptations documentation e-modules • Design: Feasibility evaluation • Process: • Research team brainstormed and compiled desired variables • Desired variables presented to partners who advised which ones are currently captured in e-modules • Data sharing agreement developed, ethics approval obtained • Data file covering all renewals and adaptations recorded in e- modules since inception of the system (Feb 2014) to Mar 2015 supplied to OPEN • OPEN team conducted descriptive analysis, determined feasibility of retrospective cohort study and developed recommendations for next steps Table 2. Descriptions of renewals and adaptations documented Acknowledgements • Thank-you to Nikki Roy and Linda Perfetto (PASI), Michael Nashat and Sandra Hanna (OnPharm Inc.) for their partnership on this project and to Abhijeet Minhas for his critical review of this poster. • This research project was supported by a grant from the Government of Ontario. The views expressed in this poster are those of the presenters and do not necessarily reflect those of the funder. Introduction Methods • In October 2012 Ontario pharmacists (RPh) gained authority to independently renew and adapt prescriptions, however to date there has been no evaluation of the uptake of these services • RPh documentations serve as data sources but earlier work examining hard-copy prescription records proved too resource intensive for a wider-scale audit • We partnered with: • OnPharm Inc. (OP) - supports 230 independent pharmacies in Ontario • Pharmacy Access Solutions Inc. (PASI) - a pharmacy documentation database vendor • Together they had developed e-modules for renewals and adaptations to be used by OP-member RPh • Overall Aim: To explore whether data from e-modules is useful for estimating uptake of renewal and adaptation authority • Research Questions: • What variables (data fields) are desired for a study describing whether and to what extent RPh are renewing and adapting prescriptions? • How useful is the currently available data? • Are the desired data fields currently being documented in the existing system? • Are a reasonable number of Ontario RPh adequately entering data into the documentation system? Category Currently Available Currently Unavailable Patient unique ID, gender, birth year, postal code Pharmacist (RPh) unique ID Pharmacy unique ID, postal code mean daily prescription volume Prescription (Rx) unique ID (Rx number), date of Rx, DIN, AHFS classification, medication name, strength, route of administration, number of refills for last filled Rx, quantity authorized for last filled Rx Renewal reason for renewal, quantity authorized by RPh, quantity dispensed by RPh, patient does not have primary care prescriber (Y/N), method of notification of primary care prescriber (phone, fax, other) days’ supply authorized by RPh Adaptation type of adaptation, quantity authorized by RPh, quantity dispensed by RPh, notification to prescriber (Y/N), method of notification of prescriber (phone, fax, other) days’ supply authorized by RPh, patient does not have primary care prescriber (Y/N) Prescriber unique ID, credentials, postal code • A retrospective cohort study estimating the uptake of renewals and adaptations through review of RPh clinical e-documentation is not feasible at this time • Analysis of data collected through e-modules feasible though changes to modules desirable to increase usefulness of data • Enhanced usage of the documentation modules by RPh in a greater number of jurisdictions is required for evaluating uptake of prescriptive authority Conclusions Fig 1. Percentage of adaptations and renewals completed by each RPh in the two pharmacies from which data were collected ID, identifier; DIN, drug identification number; AHFS, American Hospital Formulary System Pharmacy 1 Pharmacy 2 100% 0% 0% 0% 0% 0% 0% 0% 55% 15% 15% 7% 4% 1% 1% 1% RPh 1 RPh 2 RPh 3 RPh 4 RPh 5 RPh 6 RPh 7 RPh 8 PercentageofAdaptations/Renewals Adaptations Renewals